---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-009755"
form_type: "8-K"
ticker: "NXL"
cik: "0001527352"
company_name: "Nexalin Technology, Inc."
filed_at: "2025-12-05T23:59:59+00:00"
generated_at: "2026-05-16T14:14:49.647140+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "medium"
source: SEC EDGAR
---

# Nexalin releases December 2025 investor presentation; cash $4.4M, no debt, warrants expired

## Summary
- Financial snapshot: Cash $4.4M, zero debt, 18.2M common shares, 22.3M fully diluted; warrants expired Sept 2025.
- Gen-2 SYNC (15mA) in-clinic device and Gen-3 HALO at-home device with subscription model highlighted.
- Regulatory progress: FDA De Novo strategy for Alzheimer's, insomnia; clearances in China, Brazil, Oman, Israel.
- Clinical results claim 77% insomnia improvement, 74% depression improvement; Alzheimer's cognitive gains noted.
- Go-to-market includes military TBI/PTSD advisory board with former NATO Supreme Commander and DoD official.

## SEC filing metadata
- accession: 0001829126-25-009755
- form_type: 8-K
- ticker: NXL
- cik: 0001527352
- company_name: Nexalin Technology, Inc.
- filed_at: 2025-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527352/000182912625009755/0001829126-25-009755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527352/000182912625009755/nexalintech_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-009755
- JSON: https://secwatch.observer/filing/0001829126-25-009755.json
- Plain text: https://secwatch.observer/filing/0001829126-25-009755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.